Myeloproliferative Neoplasms
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
Investigational T-Cell Immunotherapy Superior to Standard HSCT in Rate of Survival Plus GvHD Freedom
A phase 3 study comparing the treatments in multiple hematologic malignancies also saw greater overall survival at one year.
The hepcidin mimetic increased hematocrit control and reduced both phlebotomy need and symptoms in a phase 2 trial.
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
The panel's discussion, moderated by Neil Love, MD, dove especially into the nuances of using avapritinib and ruxolitinib.
Detectable MRD before HSCT is associated with worse survival in patients with MDS/MPN compared with undetectable MRD.
This novel JAK2 inhibitor features reduced off-target suppression of JAK1, JAK3, TYK2, and other kinases.
Detailed findings from SURPASS-ET including pharmacokinetic and biomarker data will be presented in the future.
Efficacy and safety primary analysis findings are reported from the international, open-label FREEDOM2 trial.
Initial findings from a phase I study show the compound significantly reduces the need for phlebotomy in patients with PV.
Advertisement
Expert Interviews on Hematology
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.